临床表现性心脏结节病中ICD指征与心脏性猝死风险
芬兰1988至2017年398例临床心脏结节病患者中,按HRS指南85%有ICD指征(I/IIa类),其5年SCD累积发生率为10.7%,无指征者为4.8%,差异无统计学意义(P=0.176)。多变量分析显示组织学确诊(P=0.033)而非ICD指征(P=0.210)预测SCD。无ICD指征者5年SCD、持续性室速或新出现指征的合并发生率达53%。
要点
- 现行ICD指南未能区分临床心脏结节病中的真正低危组,无指征者5年SCD风险仍接近5%。
- 组织学确诊(而非ICD指征)是多变量分析中SCD的独立预测因素(P=0.033)。
- 无ICD指征者5年SCD、持续性室速或新出现ICD指征的累积发生率为53%。
核心结论
- 现行ICD指南未能识别临床心脏结节病中的真正低危组,无指征者5年SCD风险接近5%。
- 所有有临床心脏表现的心脏结节病患者均应考虑ICD植入。
研究设计与样本
- 回顾性分析芬兰1988至2017年398例临床心脏结节病患者,其中组织学确诊193例,可能205例。
- 按HRS 2014和ACC/AHA/HRS 2017指南评估ICD指征(I或IIa类),随访记录SCD和持续性室速。
主要发现
- 中位随访4.8年,41例(10.3%)发生致命或中止的SCD,98例(24.6%)以SCD或持续性室速为首发事件。
- HRS指南I/IIa类ICD指征者339例(85%),无指征者59例(15%)。
- 有指征者5年SCD累积发生率10.7%(95%CI 7.4%-15.4%),无指征者4.8%(95%CI 1.2%-19.1%),P=0.176。
- 多变量回归中,组织学确诊预测SCD(P=0.033),ICD指征未预测(P=0.210)。
- 无ICD指征者5年SCD、持续性室速及新出现I/IIa类指征的累积发生率为53%(95%CI 40%-71%)。
关键数值与推荐
- HRS指南I/IIa类ICD指征:有指征者5年SCD 10.7%(95%CI 7.4%-15.4%),无指征者4.8%(95%CI 1.2%-19.1%)。
- 组织学确诊者5年SCD:有指征13.8%(95%CI 9.1%-21.0%)vs无指征6.3%(95%CI 0.7%-54.0%)。
- 可能心脏结节病者5年SCD:有指征7.6%(95%CI 3.8%-15.1%)vs无指征3.3%(95%CI 0.5%-22.9%)。
- ACC/AHA/HRS指南评估的245例完整数据患者全部有I/IIa类ICD指征。
临床怎么用
- 临床心脏结节病患者即使不符合现行ICD指征,也应评估ICD植入,因5年SCD风险接近5%。
- 组织学确诊(心肌活检)可辅助SCD风险分层。
- 无ICD指征者需密切随访,5年内SCD、持续性室速或新出现指征的风险达53%。
局限性
- 回顾性观察性研究,可能存在选择偏倚和信息偏倚。
- 部分亚组样本量小,置信区间宽,统计效能有限。
- ICD植入率在有无指征组间不同(78% vs 51%),可能影响SCD结局的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac sarcoidosis (CS) predisposes to sudden cardiac death (SCD). Guidelines for implantable cardioverter defibrillators (ICDs) in CS have been issued by the Heart Rhythm Society in 2014 and the American College of Cardiology/American Heart Association/Heart Rhythm Society consortium in 2017. How well they discriminate high from low risk remains unknown. METHODS: We analyzed the data of 398 patients with CS detected in Finland from 1988 through 2017. All had clinical cardiac manifestations. Histological diagnosis was myocardial in 193 patients (definite CS) and extracardiac in 205 (probable CS). Patients with and without Class I or IIa ICD indications at presentation were identified, and subsequent occurrences of SCD (fatal or aborted) and sustained ventricular tachycardia were recorded, as were ICD indications emerging first on follow-up. RESULTS: Over a median of 4.8 years, 41 patients (10.3%) had fatal (n=8) or aborted (n=33) SCD, and 98 (24.6%) experienced SCD or sustained ventricular tachycardia as the first event. By the Heart Rhythm Society guideline, Class I or IIa ICD indications were present in 339 patients (85%) and absent in 59 (15%), of whom 264 (78%) and 30 (51%), respectively, received an ICD. Cumulative 5-year incidence of SCD was 10.7% (95% CI, 7.4%-15.4%) in patients with ICD indications versus 4.8% (95% CI, 1.2%-19.1%) in those without (χ2=1.834, P=0.176). The corresponding rates of SCD were 13.8% (95% CI, 9.1%-21.0%) versus 6.3% (95% CI, 0.7%-54.0%; χ2=0.814, P=0.367) in definite CS and 7.6% (95% CI, 3.8%-15.1%) versus 3.3% (95% CI, 0.5%-22.9%; χ2=0.680, P=0.410) in probable CS. In multivariable regression analysis, SCD was predicted by definite histological diagnosis (P=0.033) but not by Class I or IIa ICD indications (P=0.210). In patients without ICD indications at presentation, 5-year incidence of SCD, sustained ventricular tachycardia, and emerging Class I or IIa indications was 53% (95% CI, 40%-71%). By the American College of Cardiology/American Heart Association/Heart Rhythm Society guideline, all patients with complete data (n=245) had Class I or IIa indications for ICD implantation. CONCLUSIONS: Current ICD guidelines fail to distinguish a truly low-risk group of patients with clinically manifest CS, the 5-year risk of SCD approaching 5% despite absent ICD indications. Further research is needed on prognostic factors, including the role of diagnostic histology. Meanwhile, all patients with CS presenting with clinical cardiac manifestations should be considered for an ICD implantation.
引用
- Nordenswan HK, Pöyhönen P, Lehtonen J, et al. Incidence of Sudden Cardiac Death and Life-Threatening Arrhythmias in Clinically Manifest Cardiac Sarcoidosis With and Without Current Indications for an Implantable Cardioverter Defibrillator. Circulation. 2022. PMID: 36000392. doi:10.1161/CIRCULATIONAHA.121.058120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。